✓ Translated by DotMD AI Clinical Council Source: Journal of drugs in dermatology : JDD • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38443130 ↗

Phase III Randomized Trial: Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel (N = 741)

Original Paper Title: “Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel”

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 741
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Lesion count reductions were significantly greater with CAB versus its dyads and vehicle gel as early as week 4, with substantial reductions observed after 12 weeks of treatment.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of drugs in dermatology : JDD (N = 741 human participants).
  • Biostatistical Rigor Score: 93/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of drugs in dermatology : JDD (2024), this phase iii randomized trial evaluating 741 human participants investigated: A once-daily, three-pronged approach using an antibiotic, antibacterial, and retinoid may provide faster acne improvement versus monotherapy or dual-combination products. Key clinical takeaway: Lesion count reductions were significantly greater with CAB versus its dyads and vehicle gel as early as week 4, with substantial reductions observed after 12 weeks of treatment.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of drugs in dermatology : JDD, 2024-03-01; N = 741; Rigor 93/100): Lesion count reductions were significantly greater with CAB versus its dyads and vehicle gel as early as week 4, with substantial reductions observed after 12 weeks of treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: clindamycin-phosphate-topical → Rx: clindamycin-phosphate → Rx: adapalene-gel → Rx: adapalene → Condition: compulsive-scratching → Condition: perioral-dermatitis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38443130: Phase III Randomized Trial: Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel (N = 741)

3 of 3 Free Questions Remaining